Literature DB >> 30075287

PET imaging of synaptic density: A new tool for investigation of neuropsychiatric diseases.

Zhengxin Cai1, Songye Li2, David Matuskey2, Nabeel Nabulsi2, Yiyun Huang2.   

Abstract

Synaptic vesicle glycoprotein 2A (SV2A) is expressed ubiquitously in neurons of the central nervous system, and is the binding target of the anti-epileptic drug levetiracetam. Because of the availability of positron emission tomography (PET) ligands targeting SV2A, there is increasing enthusiasm on the use of SV2A PET to study a variety of neuropsychiatric diseases. This review discusses the recent development of radioligands for PET imaging of SV2A and their potential use in the research and diagnosis of CNS diseases.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Alzheimer’s disease; Autism spectrum disorder; Depression; Epilepsy; Huntington’s disease; Multiple sclerosis; PET; Parkinson’s disease; SV2A; Schizophrenia; Stroke; Synaptic density

Mesh：

Substances：

Year:  2018        PMID： 30075287      PMCID： PMC6339829          DOI： 10.1016/j.neulet.2018.07.038

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN： 0304-3940            Impact factor:   3.046


  81 in total

1.  Complement C1q-C3-associated synaptic changes in multiple sclerosis hippocampus.

Authors:  Iliana Michailidou; Janske G P Willems; Evert-Jan Kooi; Corbert van Eden; Stefan M Gold; Jeroen J G Geurts; Frank Baas; Inge Huitinga; Valeria Ramaglia
Journal:  Ann Neurol       Date:  2015-05-11       Impact factor: 10.422

2.  Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques.

Authors:  Robert M Koffie; Melanie Meyer-Luehmann; Tadafumi Hashimoto; Kenneth W Adams; Matthew L Mielke; Monica Garcia-Alloza; Kristina D Micheva; Stephen J Smith; M Leo Kim; Virginia M Lee; Bradley T Hyman; Tara L Spires-Jones
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-19       Impact factor: 11.205

Review 3.  The functional anatomy of basal ganglia disorders.

Authors:  R L Albin; A B Young; J B Penney
Journal:  Trends Neurosci       Date:  1989-10       Impact factor: 13.837

4.  Oligomers of Amyloid β Prevent Physiological Activation of the Cellular Prion Protein-Metabotropic Glutamate Receptor 5 Complex by Glutamate in Alzheimer Disease.

Authors:  Laura T Haas; Stephen M Strittmatter
Journal:  J Biol Chem       Date:  2016-06-20       Impact factor: 5.157

Review 5.  2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception.

Authors:  Michael W Weiner; Dallas P Veitch; Paul S Aisen; Laurel A Beckett; Nigel J Cairns; Jesse Cedarbaum; Robert C Green; Danielle Harvey; Clifford R Jack; William Jagust; Johan Luthman; John C Morris; Ronald C Petersen; Andrew J Saykin; Leslie Shaw; Li Shen; Adam Schwarz; Arthur W Toga; John Q Trojanowski
Journal:  Alzheimers Dement       Date:  2015-06       Impact factor: 21.566

Review 6.  Seizure characteristics and prognostic factors of gliomas.

Authors:  Melissa Kerkhof; Charles J Vecht
Journal:  Epilepsia       Date:  2013-12       Impact factor: 5.864

7.  Differential expression of synaptic vesicle protein 2 (SV2) isoforms.

Authors:  S M Bajjalieh; G D Frantz; J M Weimann; S K McConnell; R H Scheller
Journal:  J Neurosci       Date:  1994-09       Impact factor: 6.167

Review 8.  Modern techniques of epileptic focus localization.

Authors:  Lukas Martinkovic; Hrvoje Hecimovic; Vlastimil Sulc; Radek Marecek; Petr Marusic
Journal:  Int Rev Neurobiol       Date:  2014       Impact factor: 3.230

9.  Botulinum neurotoxin D uses synaptic vesicle protein SV2 and gangliosides as receptors.

Authors:  Lisheng Peng; William H Tepp; Eric A Johnson; Min Dong
Journal:  PLoS Pathog       Date:  2011-03-31       Impact factor: 6.823

10.  Alzheimer's therapeutics targeting amyloid beta 1-42 oligomers I: Abeta 42 oligomer binding to specific neuronal receptors is displaced by drug candidates that improve cognitive deficits.

Authors:  Nicholas J Izzo; Agnes Staniszewski; Lillian To; Mauro Fa; Andrew F Teich; Faisal Saeed; Harrison Wostein; Thomas Walko; Anisha Vaswani; Meghan Wardius; Zanobia Syed; Jessica Ravenscroft; Kelsie Mozzoni; Colleen Silky; Courtney Rehak; Raymond Yurko; Patricia Finn; Gary Look; Gilbert Rishton; Hank Safferstein; Miles Miller; Conrad Johanson; Edward Stopa; Manfred Windisch; Birgit Hutter-Paier; Mehrdad Shamloo; Ottavio Arancio; Harry LeVine; Susan M Catalano
Journal:  PLoS One       Date:  2014-11-12       Impact factor: 3.240
View more
  31 in total

1.  Synthesis and in Vivo Evaluation of a Novel PET Radiotracer for Imaging of Synaptic Vesicle Glycoprotein 2A (SV2A) in Nonhuman Primates.

Authors:  Songye Li; Zhengxin Cai; Xiaoai Wu; Daniel Holden; Richard Pracitto; Michael Kapinos; Hong Gao; David Labaree; Nabeel Nabulsi; Richard E Carson; Yiyun Huang
Journal:  ACS Chem Neurosci       Date:  2018-11-16       Impact factor: 4.418

2.  Synthesis and in vivo evaluation of [18F]UCB-J for PET imaging of synaptic vesicle glycoprotein 2A (SV2A).

Authors:  Songye Li; Zhengxin Cai; Wenjie Zhang; Daniel Holden; Shu-Fei Lin; Sjoerd J Finnema; Anupama Shirali; Jim Ropchan; Stephane Carre; Joel Mercier; Richard E Carson; Nabeel Nabulsi; Yiyun Huang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-06-07       Impact factor: 9.236

3.  In Vivo Synaptic Density Imaging with 11C-UCB-J Detects Treatment Effects of Saracatinib in a Mouse Model of Alzheimer Disease.

Authors:  Takuya Toyonaga; Levi M Smith; Sjoerd J Finnema; Jean-Dominique Gallezot; Mika Naganawa; Jason Bini; Tim Mulnix; Zhengxin Cai; Jim Ropchan; Yiyun Huang; Stephen M Strittmatter; Richard E Carson
Journal:  J Nucl Med       Date:  2019-05-17       Impact factor: 10.057

4.  Roadmap toward the 10 ps time-of-flight PET challenge.

Authors:  Paul Lecoq; Christian Morel; John O Prior; Dimitris Visvikis; Stefan Gundacker; Etiennette Auffray; Peter Križan; Rosana Martinez Turtos; Dominique Thers; Edoardo Charbon; Joao Varela; Christophe de La Taille; Angelo Rivetti; Dominique Breton; Jean-François Pratte; Johan Nuyts; Suleman Surti; Stefaan Vandenberghe; Paul Marsden; Katia Parodi; Jose Maria Benlloch; Mathieu Benoit
Journal:  Phys Med Biol       Date:  2020-10-22       Impact factor: 3.609

Review 5.  Synaptic plasticity and mental health: methods, challenges and opportunities.

Authors:  Lawrence G Appelbaum; Mohammad Ali Shenasa; Louise Stolz; Zafiris Daskalakis
Journal:  Neuropsychopharmacology       Date:  2022-07-09       Impact factor: 7.853

Review 6.  Novel Tracers and Radionuclides in PET Imaging.

Authors:  Christian Mason; Grayson R Gimblet; Suzanne E Lapi; Jason S Lewis
Journal:  Radiol Clin North Am       Date:  2021-09       Impact factor: 1.947

Review 7.  Neuroimaging in Schizophrenia.

Authors:  Matcheri S Keshavan; Guusje Collin; Synthia Guimond; Sinead Kelly; Konasale M Prasad; Paulo Lizano
Journal:  Neuroimaging Clin N Am       Date:  2019-11-11       Impact factor: 2.264

8.  In vivo imaging of synaptic SV2A protein density in healthy and striatal-lesioned rats with [11C]UCB-J PET.

Authors:  Majken B Thomsen; Jan Jacobsen; Thea P Lillethorup; Anna C Schacht; Mette Simonsen; Marina Romero-Ramos; David J Brooks; Anne M Landau
Journal:  J Cereb Blood Flow Metab       Date:  2020-06-14       Impact factor: 6.200

Review 9.  Alzheimer's disease.

Authors:  Philip Scheltens; Bart De Strooper; Miia Kivipelto; Henne Holstege; Gael Chételat; Charlotte E Teunissen; Jeffrey Cummings; Wiesje M van der Flier
Journal:  Lancet       Date:  2021-03-02       Impact factor: 79.321

10.  Reversal of Age-Related Neuronal Atrophy by α5-GABAA Receptor Positive Allosteric Modulation.

Authors:  Thomas D Prevot; Akiko Sumitomo; Toshifumi Tomoda; Daniel E Knutson; Guanguan Li; Prithu Mondal; Mounira Banasr; James M Cook; Etienne Sibille
Journal:  Cereb Cortex       Date:  2021-01-05       Impact factor: 5.357
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.